Traders Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of some unusual options trading activity on Thursday. Traders bought 8,459 put options on the stock. This represents an increase of approximately 208% compared to the typical daily volume of 2,742 put options.

SELLAS Life Sciences Group Trading Up 2.1 %

Shares of SLS stock opened at $1.01 on Friday. The company has a market cap of $71.08 million, a PE ratio of -1.46 and a beta of 2.41. The company’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.16. SELLAS Life Sciences Group has a 52 week low of $0.50 and a 52 week high of $1.72.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SLS. Anson Funds Management LP acquired a new position in shares of SELLAS Life Sciences Group during the third quarter worth $992,000. Geode Capital Management LLC increased its stake in SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after buying an additional 88,183 shares during the period. State Street Corp lifted its holdings in SELLAS Life Sciences Group by 30.2% in the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after buying an additional 40,500 shares in the last quarter. Virtu Financial LLC boosted its position in SELLAS Life Sciences Group by 24.1% in the 3rd quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after buying an additional 15,398 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of SELLAS Life Sciences Group during the third quarter valued at about $78,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.